Berobenatide for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes.
About 950 adults will be in this study. Berobenatide will be compared to a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. Berobenatide or placebo is given by a shot under the skin in the belly area. The objective of the study is to compare the experiences of people receiving berobenatide to those of the people who do not to assess if the study medicine is effective and safe.
People will take part in this study for about 20 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
This trial is for adults aged 18 or older who are overweight or have obesity. People can join if their BMI is at least 30, or between 27 and 30 with a weight-related health issue like high blood pressure, high cholesterol, sleep apnea, heart disease, or type 2 diabetes.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive berobenatide or placebo by subcutaneous injection to assess efficacy and safety
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Trial Overview
The study compares berobenatide (PF-08653944), given as an injection under the skin in the belly area, to a placebo that looks the same but has no medicine. About 950 participants will be randomly assigned to either group and followed for about 20 months.
How Is the Trial Designed?
5
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive PF-08653944 by Subcutaneous Injection.
Participants will receive PF-08653944 by Subcutaneous Injection.
Participants will receive PF-08653944 by Subcutaneous Injection.
Participants will receive PF-08653944 by Subcutaneous Injection.
Participants will receive matching placebo by Subcutaneous Injection.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.